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Objective. To examine the relationship between serum lipids and abdominal aortic aneurysms (AAA).
Methods. Two hundred and six males (.50 years) with AAA ( ^ 30 mm) detected in a population based screening
programme were compared with 252 age-matched male controls in a nested case–control study. Smoking status, previous
medical and family histories, height, weight, blood pressure, ankle brachial pressure index (ABPI) and non-fasting lipid
profile were recorded.
Results. Cases were found to have significantly higher LDL cholesterol than controls. LDL cholesterol was an independent
predictor of the risk for aneurysms in a logistic regression model adjusting for smoking status, family history of AAA,
history of ischaemic heart disease, presence of peripheral vascular disease, use of lipid lowering medication and treatment for
hypertension. There was a linear effect with increased levels of LDL cholesterol increasing the risk of having a small
aneurysm (test for trend p ¼ 0.03).
Conclusion. The highly significant association between LDL cholesterol and small aneurysms suggests that LDL, possibly
acting via inflammatory mediated matrix degeneration, could be an initiating factor in the development of AAA. The ability
of statin therapy to prevent AAA formation requires further investigation.
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Introduction
The role of lipids in the development of atherosclerosis
has been investigated extensively and treatment with
statins is now firmly established as part of best
medical therapy for patients with coronary and
peripheral arterial disease.1,2 Aneurysmal disease
shares many risk factors with cardiovascular disease
such as male sex, smoking and hypertension,3,4
however, data on the association between lipid
abnormalities and the risk of AAA are conflicting.
Pooled data from three studies5 – 7 demonstrated no
association between hypercholesterolaemia and an
increased risk of AAA. By contrast, other researchers
have found a relationship between serum cholesterol
and screen detected8 – 11 and with familial AAAs.12
It is well recognised that oxidized LDL is a major
cause of injury to vascular endothelium and smooth
muscle cells in the media.13 Once present within the
arterial wall, LDL excites an inflammatory response
that results in migration of macrophages and smooth
muscle cells and leads to a local increase in inflam-
matory mediators.13,14 These inflammatory processes
are thought to play an important role in the formation
of aneurysms by mediating the progressive matrix
degeneration through the expression of matrix metal-
loproteinases (MMPs).15,16 This suggests that LDL
may be an initiating factor for the inflammatory
response that sets off matrix degeneration.
This study was set up to examine the association
between lipids and small aneurysms to further
investigate the possible role of lipid abnormalities as
an initiating factor in aneurysmal disease.
Methods
A nested case–control study was performed within
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the Huntingdon male (.50 years) population based
AAA screening programme, which has been described
previously,17 with cases and controls being selected
from the screened population. A case was defined as a
person with an infrarenal aortic diameter ^ 30 mm.
Controls were matched for age using frequency
matching and were selected at random from the
screened population with an aortic diameter of less
than 25 mm. Details of current smoking status,
smoking history, family history of AAA, previous
medical history and drug history were obtained
through a self-administered questionnaire.
A positive history of ischaemic heart disease was
recorded if the patient had experienced a myocardial
infarction, had hospital treatment for angina or had
undergone a coronary artery bypass operation or
coronary angioplasty. The presence of angina was
diagnosed according to the criteria of the Rose
questionnaire.18 Diabetes and hypertension were
defined as current use of anti-diabetic or antihyper-
tensive medication, respectively, and in line with the
Edinburgh Artery study, peripheral vascular disease
was deemed present if the ankle brachial pressure
index (ABPI) was lower than 0.9.19
Measurements
All men had a brief standard medical examination by
the same observer, including measurements of height,
weight, blood pressure and ABPI. The blood pressure
was measured automatically using a Dinamap 1846
SXP (Critikon, Kettering UK). Infrarenal aortic diam-
eter was measured by the same ultrasonographer
using a Toshiba Capasee with a curvilinear 3.5 MHz
probe (Toshiba Medical Systems Ltd, Crawley, UK).
The maximal antero-posterior diameter of the infra-
renal aorta on a longitudinal scan was used as this has
been shown to be more repeatable than the transverse
diameter measurement.20 Previous work from this
group has shown that the limits of variability of the
measurement of the infrarenal aortic diameter are less
than 5 mm21 which correlates well with other pub-
lished data.20,22 Measurement of the aortic diameter
was done after the medical examination to avoid
observer bias.
At the time of the medical examination, a blood
sample was taken for measurement of serum lipid
levels. The samples were spun down and the serum
stored at 221 8C on the same day for analysis a few
days later in the department of chemical pathology at
Hinchingbrooke hospital. The lipid profile, consisting
of serum total cholesterol, HDL cholesterol, LDL
cholesterol and triglycerides was determined using
an automated procedure in a random blood sample.
Statistical analysis
Statistical analysis was performed with STATA 5.0 for
Macintosh (Stata Corporation, College Station, Texas,
USA). Lipid levels were examined by comparing mean
values. Means adjusted for smoking status, history of
ischaemic heart disease, and use of lipid lowering
drugs were calculated using linear regression23 and
compared using Fisher’s F test. A p value of 0.05 was
taken as being statistically significant. Odds ratios for
the likelihood of having an AAA were calculated for
LDL as a continuous variable, adjusting for smoking,
ischaemic heart disease, peripheral vascular disease,
hypertension and family history of AAA using a
logistic regression model.
Results
A total of 227 cases and 265 controls participated in the
study. Of these, 206 cases and 252 controls consented
to the measurement of a lipid profile and were used for
analysis in this study.
Cases and controls were well matched for body
mass index (BMI), but smoking, hypertension, a
history of cardiovascular or peripheral vascular dis-
ease was significantly more common amongst cases
(Table 1).
Lipid profile
Cases with small AAA were found to have signifi-
cantly higher mean LDL cholesterol levels than
controls (Table 2). This difference in LDL persisted
following adjustment for common risk factors by
linear regression modeling (Table 3). No significant
differences in HDL-cholesterol and or triglycerides
were found between cases with a small aneurysm and
controls.
In a logistic regression model, adjusted for age,
smoking status, family history of AAA, history of
ischaemic heart disease, history of peripheral vascular
disease, use of lipid lowering medication and treat-
ment for hypertension, LDL cholesterol remained an
independent predictor of the presence of a small AAA
(Odds Ratio (OR) (95% CI) 1.30 (1.02–1.65), p ¼ 0:03)
(Table 4). There was a linear effect with increased
levels of LDL cholesterol increasing the risk of having
a small aneurysm (test for trend p ¼ 0:03). Specifically,
each 0.1 mmol/l increase in LDL cholesterol increased
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the relative risk of the presence of a small AAA by 3%
(95% CI: 0.2–6.5%).
Other risk factors
In the logistical regression models, current smoking
was found to be the most important risk factor for the
presence of a small AAA (Odds Ratio (95% CI) 11.7
(4.0–34.2), p ¼, 0:001). In addition, a previous history
of smoking, ischaemic heart disease and peripheral
arterial disease were all found to be significantly
associated with small AAAs (Table 4).
Discussion
We performed a case–control study to overcome the
problems inherent to studying relatively uncommon
diseases with multiple aetiological factors and a long
latency period. There are, however, limitations associ-
ated with this type of study. In particular, case–control
studies have a tendency towards selection and
observation bias, which may tend to overestimate the
influence of the aetiological factors being examined.
Administering the questionnaire and performing the
clinical examination prior to ultrasound assessment
will have minimized the influence of these biases.
Nonetheless, this study has demonstrated a significant
association between raised LDL cholesterol and the
presence of small AAAs, even after adjusting for other
relevant confounders. For every 0.1 mmol/l increase
in LDL the relative risk of having an AAA increases by
3%. When this is extrapolated to the screened
population (prevalence of AAA: 5.2%24) the absolute
risk of the presence of an aneurysm increases by 0.2%
for every 0.1 mmol/l increase in LDL.
This current work confirms the findings of other
studies demonstrating a multi-factorial aetiology of
AAAs with smoking being ranked as the most
important risk factor.25,26 Data published to date on
the association between lipid abnormalities and the
risk of AAAs have, however, been conflicting. Several
epidemiological studies have demonstrated an associ-
ation between lipid levels and AAAs8 – 11 whilst others
have failed to do so.5 – 7 The major flaw with previous
association of LDL and AAAs lies with the fact that
patients with AAAs are known to have a higher
incidence of co-existing atherosclerotic disease (ischae-
mic heart disease or peripheral arterial disease).
Previously, therefore, it has not been clear whether
the observations represent a true association with
AAAs or if they simply reflect the higher incidence of
atherosclerotic disease found in this group of patients.
In concordance with these previous studies we have
shown a significantly higher incidence of co-existing
atherosclerotic disease in patients with an AAA. We
were, however, able to adjust for the presence of
ischaemic heart disease and peripheral arterial disease
in the logistic regression model. Following this
adjustment, LDL remained significantly associated
with AAAs.
The exact role of lipids in the natural history of
Table 1. Main characteristics of cases and controls.
Variable Cases ðn ¼ 206Þ Controls ðn ¼ 252Þ P value
N 206 252
Age 71 (range 54–88) 70 (range 54–87) 0.30
Aortic diameter (mm) 34 (6) 20 (2) ,0.001
BMI 26.9 (3.5) 26.5 (3.3) 0.20
Systolic blood pressure (mmHg) 159.2 (25.5) 153.7 (23.0) 0.01
Diastolic blood pressure (mmHg) 87.5 (15.7) 82.5 (14.5) ,0.001
Never smokers (%) 10 (5) 53 (21) ,0.001
History of IHD (%) 78 (38) 68 (27) 0.01
History of CVD (%) 47 (23) 40 (16) 0.11
PVD (%) 68 (33) 40 (16) ,0.001
Diabetes (%) 6 (3) 10 (4) 0.63
Family history of AAA (%) 17 (8) 8 (3) 0.01
Lipid lowering drugs (%) 19 (9) 8 (3) 0.01
History of ischaemic heart disease was defined as a myocardial infarction, hospital treatment for angina, coronary artery bypass or coronary
angioplasty. History of cerebrovascular disease is defined as a stroke or TIA (mini stroke) in the past. Peripheral vascular disease (PVD) is
defined as an ankle brachial pressure index ,0.9. Diabetes is defined as current use of anti diabetic drugs. Figures in brackets are 95%
confidence intervals around the estimate unless indicated otherwise.
Table 2. Unadjusted mean cholesterol and lipoproteins levels in
mmol/l for cases and controls.
Cases ðn ¼ 206Þ Controls ðn ¼
252Þ
P value
Mean 95% CI Mean 95% CI
Total cholesterol 5.96 5.81–6.11 5.76 5.63–5.90 0.051
HDL cholesterol 1.13 1.07–1.20 1.16 1.11–1.22 0.47
LDL cholesterol 4.05 3.92–4.19 3.71 3.59–3.83 0.0002
Triglycerides 1.97 1.76–2.17 1.98 1.80–2.17 0.91
S. D. Hobbs et al.620
Eur J Vasc Endovasc Surg Vol 26, December 2003
AAAs however, remains unclear. Recent studies have
only demonstrated a minor role for lipids in the
progression and expansion of AAAs.27 We hypoth-
esise that the association of LDL cholesterol and small
AAAs found in this study suggests that LDL choles-
terol may be more important as one of the initiating
factors associated with aneurysm formation.
Chronic inflammation is a prominent characteristic
of most AAAs in which the outer wall is infiltrated by
lymphocytes and macrophages.28,29 LDL, in its oxi-
dised form (ox-LDL), is recognised to be associated
with accelerated atherogenesis by initiating endo-
thelial and smooth muscle cell damage,13,30 inducing
production of platelet derived growth factors31 and
stimulating the migration of smooth muscle cells from
media to intima.14 Ox-LDL is more readily taken up by
monocyte-derived macrophages than LDL32 and this
uptake is known to induce an inflammatory response
resulting in the release of MMPs and urokinase-type
plasminogen activator (u-PA) which contribute to
extra cellular matrix remodeling.33
The clinical implications of these findings are
unclear and numerous issues are raised. What is the
role of lipid assessment during aneurysm screening? Is
there a role of lipid lowering therapy in the primary
treatment of aneurysms? And, is there a role for statins
in the secondary prevention of aneurysms? Statins are
a complex group of drugs that in addition to their lipid
lowering effects may have a role in reducing the
destructive remodeling of the aortic wall that occurs in
aneurysms by altering endothelial function and redu-
cing the expression of MMPs via their anti-inflamma-
tory and immune modulatory properties.34 – 36 It seems
plausible that treatment with statins may have a role in
the prevention and treatment of aneurysms, however,
randomised controlled trials assessing this issue will
be extremely difficult to realise. Further information
needs to be acquired from basic scientific research and
prospective longitudinal cohort studies.
Conclusion
This study has demonstrated a significant association
between plasma LDL levels and the presence of small
aortic aneurysms. This has led to a hypothesis that
LDL, possibly acting via inflammatory mediated
matrix degeneration, could be an initiating factor in
the development of aortic aneurysms. Further evalu-
ation of the role of LDL cholesterol in aneurysm
formation is required.
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